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1INTRODUCTION
HIV infection/AIDS is pandemic, with cases reported from nearly every
country in the world. Unlike other epidemics, AIDS falls most heavily on young
adults in their prime, posing a grave challenge in the areas of health, social and
economic development .
Demographically, being the second largest country in the world, India also
has the third largest number of people living with HIV/ AIDS. As per the Annual
HIV Report of NACO -2010, there are an estimated 22.7 lakh people living with
HIV/ AIDS in India1.2,3. The HIV prevalence in the country is 0.29 % and most
infections occur through heterosexual route of transmission.
Modes of transmission of HIV
By far, sexual route is the commonest mode of transmission of HIV
worldwide; heterosexual being more common than the homosexual route5,7. The
presence of other sexually transmitted diseases has been strongly associated with
susceptibility to infection and infectivity with micro-organisms like Treponema
pallidum, Hemophilus ducreyi, Herpes simplex virus type 2, etc.
HIV can also be transmitted to individuals who receive HIV-tainted blood
transfusion, blood products or transplanted tissues as well as to intravenous drug
2users (IDUs), who are exposed to HIV while sharing injections, needles, syringes,
water in which drugs are mixed, cotton through which drugs are filtered, etc.
Subcutaneous and intramuscular injections can transmit HIV as well.
Occupational exposures can spread HIV to health care workers via
percutaneous injuries or contact of mucus membrane or non-intact skin with blood,
tissue, or other potentially infectious body fluids.
Also, HIV infection can be transmitted from an infected mother to her fetus during
pregnancy, delivery or breast feeding. Most commonly maternal transmission to
the fetus occurs in the perinatal period10
Routes of transmission Percentage
Heterosexual 87.1 %
Parent to Child 5.4 %
Intravenous  Drug user 1.6 %
Homosexual 1.5 %
Blood and Blood products 1.0 %
Unknown 3.3 %
HIV and other Sexually transmitted infections (STIs)
The knowledge of coinfection of STIs with HIV is essential in making
syndromic approach in the management of STIs and changes in the highly active
3anti-retroviral therapy (HAART) in specific situations as in herpes simplex virus
type 2, hepatitis B and C coinfections.
HBV and HCV co-infections in HIV positive individuals is of utmost
importance due to the underlying consequences such as the hepatological problems
associated with these viruses, which have been shown to decrease the life
expectancy in the HIV-infected patients. Co-infections of hepatitis-B (HBV),
hepatitis-C (HCV) and syphilis are a major concern in HIV/AIDS patients. HIV,
HBV and HCV share modes of transmission and hence co-exist in the same host at
significantly high rates. Enormous evidences are available indicating that syphilis
increases the risk of HIV infection. 4,6
The prevalence of co-infection with HIV varies widely across different
studies within India and outside. Therefore, it is important to find out regional
prevalence of these co-infections. Moreover, co-infections with the HIV have
become a major health care catastrophe. Hence, it is important to identify them
early to reduce the morbidity, delay mortality and improve quality of life in
HIV/AIDS patients. According to HIV prevalence rates in adult population, the
state of Jammu and Kashmir in India has been placed in low prevalence
state. However, in this state the disease has begun to show its ugly face in the
recent time and there is a dearth of such data of co-infection in HIV/AIDS patients.
4This is a prospective study to find out associated infections like, HBV, HCV,
syphilis in HIV/AIDS patients.
Worldwide, most adults acquire atleast one STI and many remain at risk for
complications including genital neoplasms; certain STIs such as syphilis,
gonorrhea, HIV infection, hepatitis B and C and chancroid are most concentrated
within core populations characterized by high rates of partner change, multiple
concurrent partners or highly connected sexual networks – e.g. involving
prostitutes and their clients, some homosexual men and persons involved in the use
of illicit drugs.
The initial rate of spread of any STI within a population depends on three
factors – rate of sexual exposure to infectious people, efficiency of transmission
per exposure and duration of infectivity of those infectivity. Among STIs, HIV has
become the leading cause of death in some developing countries and HPV and
hepatitis B viruses remain important causes of cervical and hepatocellular
carcinoma respectively – two of the most common malignancies in the developing
world.
5Sexually transmitted HSV infections now cause most genital ulcer disease
throughout the world and an increasing proportion of cases of genital herpes in
developing countries, with HIV epidemics.
The coincidence of syphilis with HIV and the probable resurgence of
syphilis in these patients is also being noted worldwide, more so in the developing
countries. The presence of genital ulcers is likely to increase the transmission of
other STIs, including HIV, in such patients.
The common manifestations of STIs are urethritis, epididymitis,
vulvovaginal infections including trichomoniasis, bacterial vaginosis,
mucopurulent cervicitis, pelvic inflammatory disease, genital ulcer, proctitis,
enteritis, etc.
6AIMS AND OBJECTIVES
? To study the prevalence of co-infection of HIV patients with syphilis, herpes
simplex-2, hepatitis B and hepatitis C.
? To study the demographic profile of these four STIs in HIV patients.
? To study the clinical profile of these four STIs in HIV patients.
? To study the impact of these STIs in HIV patients in various laboratory
parameters like CD4, liver function tests and ultrasonography of abdomen.
7REVIEW OF LITERATURE
INDIAN EPIDEMIOLOGY OF HIV/STI CO-INFECTION
An emerging epidemic of human immunodeficiency virus (HIV) infection in
India has made sexually transmitted infection (STI) control as one of the strategies
imperative and probably the most important one to decrease HIV transmission8
Sexually transmitted Diseases particularly genital ulcer diseases are major
public health problem in India. They play an important role in the transmission of
HIV & two have been observed to be interrelated from September 2002 to January
2003, 331 patients who were confirmed cases of HIV were included in the study
group(Screening for HIV was done by ELISA, those who were found positive were
tested by repeat ELISA utilizing another blood sample & considered HIV
seropositive only if both samples were found to be positive). All the serum samples
were then subjected to VDRL  and confirmed by TPHA for serodiagnosis of
Syphilis. Of 331 HIV positive patients,15 (4.57%) were found to be VDRL
reactive. ALL the VDRL reactive patients had high titres. Twelve of the patients
were also found to be  TPHA positive thus confirming the diagnosis of Syphilis in
these patients. Mean age of patients was 30.1 years and most of these patients were
asymptomatic and might be having early Syphilis at the time of screening. Thus
routine surveillance for Syphilis should be carried out in HIV infected individuals
8particularly to diagnose asymptomatic Syphilis so that appropriate interventions
can be taken to prevent the disease
Test Positive No (%) Negative No (%)
VDRL 10 (4.34) 220 (95.66)
Anti-HSV-2 20 (8.68) 210 (91.32)
HBsAg 8 (3.4) 222 (95.62)
Anti-HCV 0 (0) 230 (100)
The prevalence of HSV-2 and syphilis was 10.1% and 1.7%, respectively.
Geographic differences in HSV-2 prevalence were significant, while for syphilis it
was comparable. Urban–rural differences in prevalence were only seen for
syphilis. For both infections, the prevalence between males and females was not
significantly different. In males and females, HSV-2 prevalence increased
significantly with increasing age; for syphilis, a slight trend was seen only in
females. In a multivariable analysis, HSV-2 infection in males and females was
associated with site, religion and testing positive for syphilis, in addition to
reporting ?2 lifetime partners in the previous year among males and being ever
married or having had sex with a non-regular partner in the last year among
females.
9In Asia, HSV seroprevalence studies are sparse and they have recorded
lower prevalence of HSV infection, especially HSV-29 study included 135
consecutive STD cases having history of ulcerative or non-ulcerative STD in the
present or in the past 5 years and 135 age and sex-matched controls. Diagnostic
serology was done for HSV-1 and HSV-2 using type specific IgG by indirect
immunoassay using ELISA. The results were analyzed utilizing Chi- square test.
Amongst 135 STD clinic cases, 106 cases were males and 29 cases were females
with male to female ratio of 3.65:1. The mean age was 32.2 years (range 16-65
years). Among study group cases, 112 (82.9%) cases were co-infected with HSV-1
and HSV-2, 11 (8.1%) cases were seropositive for HSV-1 alone and 3 (2.2%) cases
were seropositive for HSV-2 alone. In the control group, 112 (82.9%) cases were
co-infected with HSV-1 and 2, 12 (9.6%) for HSV-1 alone and 1(0.8%) for HSV-2
alone. Correlation of HSV-1 and HSV-2 serology with various demographic and
behavioral factors was statistically insignificant.: Seroprevalence of HSV-1 and
HSV-2 in STD clinic cases and control group is high, similar to that recorded in
sub-Saharan Africa. Thus, serological studies for HSV-1 and HSV-2 cannot be
taken as a marker of sexual behavior in our set of population
HIV/AIDS cases were diagnosed as per the NACO, 2000 criteria. The
following screening tests were used to evaluate associated infections, HBsAg
micro  screen  ELISA  Test  Kit  (for  hepatitis  B);  HCV  micro  ELISA
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(3 rd generation): for detection of antibodies to Hepatitis C virus in human
serum/plasma and Rapid plasma reagin test (RPR Test) for rapid serological
diagnosis of syphilis.
Among 230 HIV/AIDS patients enrolled, HBsAg was positive in eight cases
(3.47%); anti Hepatitis C antibody was present in none of the cases. Ten (4.34%)
out of 230 cases were positive for VDRL
CD4 count was less than 200 mm 3 in 73 patients in HIV alone, , six in HBV
and five patients in syphilis co-infection group. Sixty patients recorded absolute
TLC less than 1200/cm 2 in HIV alone group. Whereas three and four patients
recorded absolute TLC less than 1200 mm 3 in, HBV and syphilis co infection
groups respectively. All HBV patients were asymptomatic and syphilis was
diagnosed in only 10 patients after performing VDRL in all the HIV diagnosed
patients. All diagnosed patients were of primary syphilis. Among the total
diagnosed patients with syphilis were treated with Benzathine penicillin G, 2.4 MU
IM in a single dose.
This study documents fairly high rates of HBV and syphilis co-infection
among HIV infected persons. Thus, it should be mandatory to screen every
HIV/AIDS patient for co-infection and vice-versa for early detection and a
11
simultaneous treatment besides HIV infection management to combat the menace
of this dreadful disease.
2456 adults were surveyed in Hyderabad, Bangalore and Chandigarh in
India. Socio-demographic and lifestyle characteristics were obtained through a
questionnaire, and a dried blood spot (DBS) was collected from all individuals
aged 18 years and over; sexual behaviour was collected from those aged 18–49
years. DBS samples were tested for HSV-2 and syphilis serology. The association
between HSV-2 and syphilis infections with socio-demographic and behavioural
variables was analysed using multivariable logistic regression.
12
SYPHILIS
Syphilis is a sexually transmitted disease caused by the spirochetal
bacterium Treponema pallidum subspecies pallidum. The route of transmission of
syphilis is almost always through sexual contact, although there are examples of
congenital syphilis via transmission from mother to child in utero or at birth.
HIV AND SYPHILIS
The interaction of syphilis and HIV infection is complex. Epidemiological
studies demonstrate that STIs, including syphilis, are associated with an increased
risk for HIV infection among both homosexual and heterosexual
persons. [11],[12] Presumably sexual behaviours that increase the risk for acquiring
STIs also increase the risk for HIV transmission. Furthermore, ulcerations and
inflammation caused by STIs are implicated as the cofactors for acquiring HIV
infection. Recent data suggest that in the presence of other STIs, individuals are
three to five times more likely to acquire HIV if exposed to the virus through
sexual contact. [3]
The diagnosis of syphilis may be more complicated in the HIV-infected
patients. Unusual serological responses have been reported in syphilis, namely,
higher than expected serologic VDRL titers. But false positive results have been
reported in HIV-infected patients with syphilis and specific tests like Fluroscent
13
Treponemal Antibody Absorption test (FTA-ABS) or Treponema pallidum
hemagglutination Assay (TPHA) would be beneficial.
Proper treatment of syphilis will go long way in preventing HIV infection.
Hence the study was undertaken to determine the prevalence of syphilis in HIV-
seroreactive patients with high-risk behaviour and to correlate age, sex and clinical
presenting complaints with HIV seroprevalence and prevalence of syphilis
The course of syphilis in HIV-positive patients with depressed immune
function is thought to differ from that in HIV-negative patients. Animal models
suggest that cell-mediated immunity plays a role in clearing Treponema
pallidum infections; lack of such immunologic control may prevent complete
eradication of infection, particularly at sanctuary sites such as the central nervous
system (CNS) or the eye. HIV coinfection has been associated with a higher titer
Rapid Plasma Reagin (RPR), multiple primary chancres, more rapid progression to
tertiary manifestations, increased frequency of ocular disease, delay or failure of
titer decline following treatment, and predilection for development of the Jarisch-
Herxheimer reaction compared with syphilis infection alone14 15 16 Coinfected
patients may also experience slower resolution of primary chancres, and, in cases
of neurosyphilis, of cerebrospinal fluid (CSF) pleocytosis, protein elevation and
Venereal Disease Research Laboratory (VDRL) titer.19 21 24 Several reports indicate
14
that HIV-coinfected patients may be at higher risk for syphilis relapse than are
HIV-negative patients.19-21.22,25,   Features of secondary syphilis may be particularly
pronounced in HIV-coinfected patients.
.CLINICAL MANIFESTATIONS:
The numerous manifestations of neurosyphilis are highly variable, ranging
from ocular syphilis (most commonly uveitis) to meningovascular disease
(manifesting as stroke), to tabes dorsalis (a disease of the posterior columns of the
spinal cord and nerve roots). Neurologic manifestations are generally classified as
"early" or "late." Early manifestations, which affect tissues derived from
mesodermal structures, include syphilitic meningitis, meningovascular disease,
labyrinthitis, meningomyelitis, and cranial nerve palsies. Late manifestations,
which affect sites of ectodermal origin, include tabes dorsalis, general paresis,
CNS gumma, and other parenchymal diseases. Late manifestations generally occur
5 to 15 years from the date of infection but may be accelerated in patients with
HIV disease16,17,20,22,28,29. Ophthalmic disease (e.g., uveitis, keratitis, optic neuritis,
conjunctivitis, optic atrophy, or chorioretinitis) is particularly common in HIV-
coinfected individuals. In a study of 46 patients with neurosyphilis, Katz and
colleagues reported ophthalmologic abnormalities in 42% of 24 HIV-positive
patients compared with 14% of 22 HIV-negative individuals. 22 Patients with
15
neurosyphilis presenting with eye disease may be otherwise asymptomatic.
Nonetheless, all patients with ocular syphilis should undergo LP and should be
treated with a standard neurosyphilis regimen. The purpose of LP in these patients
is to establish whether CSF abnormalities are present; if so, a follow-up CSF exam
is indicated 6 months after treatment to establish resolution of these findings.
Failure to see either a reduction in pleocytosis or clearance of CSF-VDRL should
prompt repeat therapy.
FREQUENCY OF NEUROSYPHILIS IN HIV-INFECTED PATIENTS:
HIV infection may increase the frequency or accelerate the development of
neurologic sequelae of syphilis, including early pathologies such as acute syphilitic
meningitis and late pathologies such as CNS gummatous lesions. Berger reported 2
HIV-infected patients (CD4 counts, 274 and 10 cells/mm3) who presented with
seizures and who were each found to have an enhancing lesion on head imaging.
Toxoplasma serologies and bacterial, fungal, and mycobacterial CSF cultures were
all negative; syphilis serologies were positive; biopsy material was consistent with
gumma formation; and clinical/radiographic response to intravenous penicillin
therapy was seen. 20 In 1 patient, contact tracing revealed exposure to syphilis only
6 months earlier. Horowitz and colleagues described a similar case treated for
primary syphilis who presented 4 years later with CNS gumma (CD4 count, 9
16
cells/mm3). Such rapid progression to previously regarded "late" complications of
neurosyphilis was largely unprecedented in the pre-HIV era.
DIAGNOSIS
The lack of a practical and readily available gold-standard test makes the
diagnosis of neurosyphilis challenging. Diagnosis relies on integrated findings of
positive serum non-treponemal and confirmatory antibody in conjunction with
neurologic or ophthalmic symptoms, CSF pleocytosis or elevated protein, and/or a
reactive CSF-VDRL. In the HIV-infected population, diagnosis may be further
challenged by atypical serologic tests (unusually high, low, or fluctuating titers). 18,
30  False-positive RPR and treponemal confirmatory tests can occur due to
concomitant cross-reacting infections or HIV-related B-cell dysfunction23
Waning serum treponemal antibody titers can be seen with AIDS, and false-
negative  CSF-VDRL  results  can  occur  in  20%  to  70%  of  patients  with  CNS
disease. False-positive CSF-VDRL is an infrequent occurrence, but can be seen
when blood contaminates the CSF.15, 27  Microhemagglutination T.
pallidum(MHA-TP) and fluorescent treponemal antibody absorption (FTABS)
tests have been used on CSF samples and are thought to be less specific than CSF-
VDRL, though significantly more sensitive. Use of these confirmatory tests in the
CSF is therefore regarded as having a high negative predictive value for
17
neurosyphilis -- some experts contend that a negative CSF FTA-ABS may exclude
this diagnosis.27, 30  The CSF abnormalities commonly seen with HIV disease make
mild pleocytosis or elevated protein very challenging to interpret and present the
greatest challenge to current diagnostic schema for neurosyphilis
HERPES SIMPLEX VIRUS TYPE 2
Sexually transmitted infections (STIs) are markers of high risk sexual
behaviour in an individual/spouse/sexual partner. Infections due to herpes simplex
virus (HSV) are extremely common. While most infections are asymptomatic or
mild, some can be transmitted to neonates and are associated with other STIs and
cervical neoplasia. HSV-2 may contribute more to human immunodeficiency virus
(HIV) infection because of its higher frequency than other STIs. Thus, because of
the recurrence of genital herpes, high prevalence of genital herpes in populations at
risk for HIV infection and large number of herpes infected persons who continue
their sexual activities despite being infectious, genital herpes is a risk factor for
acquisition of HIV-1 infection. HSV-2 infection is also significantly associated
with syphilis. Considering that herpes is a life long infection, not cured by
antimicrobial treatment, HSV-2 antibodies are a much more reliable indicator of
risky behaviour than than T.PALLIDUM antibodies.  However, a large number of
genital infections are also caused by HSV-1. The present study was thus
18
undertaken for finding IgM antibodies against HSV-1 and HSV-2, antibodies to
HIV-1 and 2 and screening for syphilis in STD patients
Out of 250 STD patients, 136 (54.4%) were males while 114 (45.6%) were
females. Forty-four of these (17.6%) were positive for HSV-1 and 2 IgM
antibodies. Out of these, 25 (56.8%) were males and 19 (43.2%) were females.
Eleven of 44 (25%) patients were positive for HIV-1 and 2 and 10/44 (22.7%)
were reactive to VDRL antigen and TPHA positive. HSV seropositive persons had
mixed clinical feature while most HIV reactive or VDRL reactive persons had
genital ulcers with or without other features. Seven of 44 (15.9%) patients were
reactive to both HIV-1 and 2 antibodies and VDRL antigen. In the asymptomatic
group, 12/50 (24%) women were positive for HSV, while none was reactive to
HIV antibodies or VDRL antigen. Highest HSV seroprevalence in STD patients
was in the age group of 21-30 years (45.5%) and who were of young age at first
sexual contact, i.e., 15-25 years (97.7%). Prevalence was also high in housewives
(40.9%), patients with non-specific discharge (50%) and genital ulcers (34.1%).
Prevalence in bad obstetric history (BOH) and mouth ulcer cases was 1/44 (2.27%)
each. Prevalence was also high in illiterate patients (70.4%) and those with
multiple partners (56.8%). Co-infection with HSV and HIV was found in 11/44
(25%) patients. Ten out of 44 (22.7%) persons were reactive to both HSV
antibodies  and  VDRL  antigen.  The  three  STIs  (HSV,  HIV  and  syphilis)  were
19
present in 7/44 (15.9%) patients. In the control group, seropositivity was high in
the age group of 21-30 years (50%) and in those who were of young age (15-25
years) at first contact (91.6%).
HSV seropositivity was highest in the young age group of 21-30 years
because of their sexually active life 31, 32  Adolescents are known to be at increased
risk of acquiring STIs because of fewer protective antibodies and increased
susceptibility of cervix.32 Seropositivity was more in housewives as most women
have little awareness of sexual and reproductive life and symptoms are generally
ignored.33 Also, transmission of HSV-2 is more efficient from men to women
compared with women to men.33 Seropositivity was high in illiterate persons
because of ignorance and in persons with multiple partners because of high risk
behaviour. High seropositivity was also seen in persons with non-specific
discharge and genital ulcers. 34, 35 Regarding prevalence in BOH cases, 36  HSV is
one of the TORCH organisms and infection in pregnancy accounts for half of the
morbidity and mortality among neonates. 37  It  may  also  lead  to
abortion/prematurity/intrauterine growth retardation and disseminated infection of
neonates.36,38  HSV  predisposes  to  other  STIs  as  it  causes  mucosal  erosions  and
may increase the concentration of HIV and other STIs in semen and vaginal fluids.
In the control group, a seropositivity of 12/50 (24%) for HSV-1 and 2 was seen.
Women are more vulnerable to STIs as they have less say in the contraception
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methods, less opportunity for early diagnosis and treatment and are more prone to
infections because of procedures like MTP, IUD insertions etc. 39. Asymptomatic
shedding can infect their neonates and they themselves are at more risk to develop
cervical cancer,40 therefore, it is important to screen them.
In summary, this study shows that genital herpes infection is a risk factor for
acquisition of HIV and other STIs and the study of seroprevalence of HSV in STD
patients is important to plan STI control strategies which may help keeping the
HIV status at a low level.
Herpes simplex virus (HSV) infections are among the most common
infections worldwide and cause recurrent infections throughout life. Transmission
is facilitated by the frequent recurrence of infectious episodes of sub-clinical viral
shedding.  Moreover, there is increasing evidence that HSV-2 infection could
significantly enhance the rates of sexual transmission and acquisition of HIV.
Increasing evidence demonstrates a substantial link between the epidemics
of sexually transmitted HIV-1 and herpes simplex virus (HSV)-2 infection. More
than 30 epidemiologic studies have demonstrated that prevalent HSV-2 is
associated with a 2- to 4-fold increased risk of HIV-1 acquisition. Per-sexual
contact transmission rates among couples from Rakai, Uganda indicate that at all
levels of plasma HIV-1 RNA in the source partner, HSV-2-seropositive HIV-1-
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susceptible persons have a 5-fold greater risk of acquiring HIV-1 compared with
HSV-2-negative persons. In vitro and in vivo studies suggest that mucosal HIV-1
shedding is more frequent and in greater amounts during mucocutaneous HSV-2
replication, including subclinical mucosal reactivations. Most HIV-1-infected
persons are coinfected with HSV-2, and most experience frequent subclinical and
clinical reactivations of HSV-2. Subclinical HSV reactivation elevates serum HIV-
1 RNA levels, and daily therapy with acyclovir appears to reduce plasma HIV-1
RNA. These data show that greater attention to the diagnosis and treatment of
HSV-2 among HIV-1-infected persons is warranted, especially those who continue
to be sexually active, those not on antiretroviral therapy, or those whose disease is
not well suppressed by antiretrovirals.
Persons 15-49 years old from 32 rural and 34 urban clusters were sampled
using a stratified random method to represent adults in the high HIV prevalence
Guntur district in Andhra Pradesh state. Interviews were conducted and dry blood
spots were collected on 12,617 study participants. Testing for HSV-2 and syphilis
was performed.
Adjusted HSV-2 and syphilis seroprevalence rates were 4.70% and 2.08%
for men and 7.07% and 1.42% for women. For men, tattooing, >3 lifetime sex
partners, tobacco use, and sex with men in the past 6 months were associated with
HSV-2 or syphilis (ORs, 1.66-2.95, p < 0.05). Male circumcision was positively
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associated with HSV-2 infection (OR, 1.37, p = 0.028) though this could be due to
residual confounding. In women, greater than one lifetime partner remained
significantly associated with HSV-2 in multivariate analysis (OR, 2.61; 95% CI,
1.39-4.87). Among all behavioral risk factors and other covariates in women and
men, HIV infection exhibited the strongest association with HSV-2 and syphilis
(ORs, 8.2-14.2, p < 0.001). The proportion of individuals with HSV-2 who were
HIV infected was less than the proportion with syphilis who were HIV infected
(11.8% vs. 22.7%; p = 0.001).
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HEPATITIS B
Hepatitis B virus is an hepadnavirus—hepa from hepatotrophic and dna
because it is a DNA virus—and it has a circular genome composed of partially
double-stranded DNA. The viruses replicate through an RNA intermediate form by
reverse transcription, and in this respect they are similar to retroviruses.
Epidemiology of HIV and hepatitis B co infections.
Co infection with human immunodeficiency virus (HIV) and hepatitis B
virus  (HBV)  is  common  due  to  shared  routes  of  transmission.  In  areas  of  low
endemicity, such as North America, Australia and Europe, HBV and HIV infection
are usually acquired in adulthood through sexual or percutaneous transmission. In
areas of low endemicity, the prevalence of chronic co infection is around 5-7%
among HIV-infected individuals 41 In countries with intermediate and high HBV
endemicity, the main routes of transmission of HBV are perinatal or in early
childhood; in these countries HBV co infection rates are 10-20% 60, 61
Impact of co infection on the natural history of HBV and HIV
The rate of progression and complications from viral hepatitis are
accelerated in patients with HIV co infection 62,63. After acquiring HBV infection,
HIV infected individuals are 6 times more likely to develop chronic hepatitis B
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than HIV negative individuals 44 .This was more likely to occur in HIV infected
men with lower CD4 cells 44 .Decreased rates of clearance of HBeAg and increased
HBV replication are also seen, with higher HBV DNA viral load 46 .In addition,
HIV infected individuals are more likely to lose previously developed protective
anti-HBs antibody and develop acute hepatitis B infection; this risk is also
associated with lower CD4 counts 43, 58 . Following initiation of antiretroviral
therapy (ART), immune reconstitution inflammatory syndrome (IRIS) may occur
which can lead to worsening liver disease including hepatic decompensation 49. In
addition, after discontinuation of an ART regimen containing anti-HBV agents,
reactivation of hepatitis B can occur: ALT elevations occurred in 29% of 147
patients within 6 months of withdrawal42. If reactivation occurs, resuming an agent
that is active against HBV is required.
HIV also hastens the progression of HBV related liver disease. Cirrhosis is
more common despite lower ALT levels than in HBV mono-infection and is also
more common with lower CD4 counts 46, 47 . HIV-HBV co-infected men are greater
than 17 times more likely to die of liver related causes compared to those   mono-
infected with HBV 67. The impact of co infection is especially important in regions
with widespread use of ART 54.  As  the  use  of  ART  becomes  more  prevalent  in
parts of the world with high HBV endemicity and long term survival increases, it is
likely that liver disease from chronic hepatitis B in HIV-infected population may
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emerge as a greater public health problem than before 53 . It is unclear at present if
the risk of hepatocellular carcinoma (HCC) is increased, but there is some evidence
that HIV infected individuals with lower CD4 counts are at greater risk of
developing HCC 45 For individuals on ART, co infection with chronic hepatitis B
increases the risk of hepatotoxicity from ART three-fold to five-fold 63,66
Assessing for HBV and its sequelae in HIV co infection
Accurate assessment of HBV infection in HIV co-infected individuals is
necessary in order to base therapeutic decisions 67 .WHO advocates HBsAg testing
especially in areas of high HBV prevalence (WHO, 2006) but additional testing for
HBV markers such as HBeAg and HBV DNA and to assess stage of liver disease
(e.g. liver enzymes, liver biopsy, etc) may not be widely available in many
resource limited countries. For HIV infected individuals with chronic HBV,
additional screening for co infection with HCV is recommended; hepatocellular
carcinoma screening with alpha fetoprotein and imaging of liver every 6 months is
being  suggested  by  some but  the  cost  Benefit  of  one  or  both  tests  as  well  as  the
frequency of monitoring in various health Economies remain to be assessed. Liver
biopsy remains the gold standard for assessing disease severity in HIV-HBV co
infection . Non-invasive markers are also available but none have been widely
studied in co-infected patients. Hoffman and Thio provide management
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recommendations for use in areas with limited resources They recommend that
HBsAg and liver enzymes be tested before ART, with liver enzymes being
repeated once or twice during the first 3 months after commencing ART. Detection
of HBV DNA is helpful but may not be available. Chronic HBV carriers with
HBeAg positivity may benefit from starting anti-HB  therapy early.
Transmission
Transmission of hepatitis B virus results from exposure to infectious blood
or body fluids containing blood. Possible forms of transmission include sexual
contact, blood transfusions, re-use of contaminated needles & syringes,
and vertical transmission from mother to child during childbirth. Without
intervention, a mother who is positive for HBsAg confers a 20% risk of passing the
infection  to  her  offspring  at  the  time  of  birth.  This  risk  is  as  high  as  90%  if  the
mother is also positive for HBeAg. HBV can be transmitted between family
members within households, possibly by contact of nonintact skin or mucous
membrane with secretions or saliva containing HBV.However, at least 30% of
reported hepatitis B among adults cannot be associated with an identifiable risk
factor.
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HEPATITIS C
                        Hepatitis C is an infectious disease affecting the liver, caused by the
hepatitis C virus (HCV). The infection is often asymptomatic, but once established,
chronic infection can progress to fibrosis and cirrhosis which is generally apparent
after many years. In some cases, those with cirrhosis will go on to develop liver
failure or other complications of cirrhosis, including liver cancer
Although injection drug use is the most common route of HCV infection,
any practice, activity, or situation that involves blood-to-blood exposure can
potentially be a source of HCV infection. The virus may be sexually transmitted,
although this is rare, and usually only occurs when an STD that causes open sores
and bleeding is also present and makes blood contact more likely.[14]
Sexual activities and practices were initially identified as potential sources
of exposure to the hepatitis C virus. More recent studies question this route of
transmission. Currently, heterosexual vaginal intercourse is thought to be a rare
means of transmission of hepatitis C infection.
         In 2005, G8 leaders promised that by 2010 Universal Access to HIV
prevention, treatment, care and support would be widely available. Since then,
much has been accomplished and over 2 million people are now on anti-retroviral
treatment. However, as people with HIV live longer, opportunistic and related
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illnesses that threaten their health are exposed. Whilst Hepatitis C is an adjunctive
rather than opportunistic disease, there is growing awareness that co-infection with
the Hepatitis C virus (HCV) is an important issue in HIV prevention, treatment,
care and support. Thus, for universal access to be fully realized, HIV/HCV co-
infection must be addressed.
To date, research on the extent of HIV/HCV co-infection is scarce. This lack
of research data is particularly profound in developing countries, where practical
methods to address these dual threats are limited. What is known, however, is that
many of those infected with HCV are also co-infected with HIV and dealing with
its impact.68  This combination creates a terrible synergy. Co-infection can worsen
the effects of both diseases. For example, if co-infected with HCV and HIV, the
chances of developing liver disease are much higher and decisions around
appropriate treatment for both diseases becomes far more complicated. It is clear
that a comprehensive approach is essential 69,70,71,72. As such, HIV advocates and
professionals must be educated about HIV/HCV co-infection and must address this
dual challenge in their future efforts.
Until 1989 Hepatitis C, a viral infection that affects the liver, was referred to
as 'non A, non B hepatitis . The WHO estimates that 3% of the world's population
(approx. 170 million people) is living with HCV. The medications used in HCV
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treatment, pegylated interferon and ribaviron, are costly and may need to be
administered for up to a full year74, 76, 78. Side effects often make adherence to
treatment challenging. The resulting liver disease caused by hepatitis is becoming a
major cause of illness and death among those infected with HIV.
HCV is also the most common virus affecting the world's 16 million
injection drug users (IDUs). It's estimated that close to 3 million IDUs are living
with HIV and some studies indicate that over 90% of IDUs infected with HIV are
also infected with HCV.
Although there are similarities between HCV and HIV transmission, there
are differences in transmission efficiencies. Rates of transmission where recipients
receive blood or blood products that are infected with HCV are close to 100%.
HCV is very easily transmitted through sharing equipment used for injecting,
smoking or snorting drugs (needles, syringes, pipes and straws) and exposure to
injection-related paraphernalia, such as cotton, water, tourniquets, swabs and
spoons ('cookers') can also result in transmission 81,82,83,84.  Other  objects  that  are
easily contaminated with blood such as piercing and tattoo equipment and ink,
razors, toothbrushes and unsterilized medical equipment, are also implicated in
transmission.
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Although HCV can be transmitted sexually and vertically (from mother to
child), until recently these kinds of exposures were thought to be insignificant.
However, recent research suggests that outbreaks of acute HCV among HIV-
positive gay and bi-sexual men who have unprotected anal intercourse are related
to sexual transmission.
Hepatitis C virus infection may remain asymptomatic for long periods of
time, and liver damage that occurs during this period may eventually lead to
chronic liver disease which may progress to liver failure. Due to the fact that 10 to
20 years can elapse between infection and the onset of liver disease, those who are
HCV-positive may unknowingly be spreading the disease. In the instance of
HIV/HCV  co-infection,  liver  damage  due  to  HCV  tends  to  occur  faster  than  in
HIV-negative people.
Although treatments are available, their effectiveness ranges from 40% to
80%, depending on the genotype (or strain) of HCV. It's important to note that
these rates are for those who are dealing with HCV alone. Unfortunately, treatment
success is reduced amongst those who are co-infected.
There is no vaccine to prevent HCV infection and researchers face
formidable challenges in vaccine development because of the virus' propensity for
mutation.
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HIV and HCV Co-infection
As noted above, HCV/HIV co-infection compromises immunity, making
HCV more likely to be transmitted and more difficult to treat. While there is no
proof that people with HCV are more susceptible to HIV infection, it is clear that
AIDS is complicated by the liver symptoms associated with HCV79,80. Treatment
presents additional challenges as many anti-retroviral drugs are cleared from the
body by the liver. Depression is another complication of HCV treatment and adds
an extra burden for those living with HIV who are already dealing with HIV-
related psychosocial and economic challenges.
In this co-infection,spontaneous viral clearance and clearance with treatment occur
less frequently. They are also more likely to develop fibrosis or other symptoms
than mono-infected patients. They are more than twice as likely as mono-infected
patients to develop it much more rapidly –in as few as ten years after infection.
They may also be at greater risk for liver cancer than mono-infected patients. Their
risk is six times greater for hepatic decompensation develops is significantly
shorter.
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HIV/Hepatitis C co-infection in the developing nations
Current data about co-infection in the developing world is inadequate. A
limited number of reviews provide some information about mono-infection in the
general population and among people who use drugs. The following sections give a
regional overview of HCV infection and HCV/HIV co-infection prevalences.
South East Asia: The HCV prevalence rate for South-East Asia as a whole was
reported as 2.15% in a 1999 review by the WHO. A recent global review of HCV
among IDUs reported rates as high as 90% in Indonesia, India, Thailand, Viet Nam
and Bangladesh. HIV/HCV co-infection rates were also extremely high in China
(99.3%) and Chang Mai, Thailand (100%). Injection drug use in these regions is
increasing. Harm reduction, at least in theory, is becoming more accepted. In
practice, however, only 3% of people who inject drugs in South Asia and 8% in
East Asia currently have access to harm reduction and many countries - Thailand,
Viet Nam and Indonesia among them - continue to criminalize drug use.
Eurasia: The countries of Central and Eastern Europe and Central Asia
experienced the fastest growing HIV epidemic globally, after a rapid rise in drug
use in the 1990s. HCV was of less concern, with rates of only 2% in 1999. Rates of
HCV infection, as well as HIV/HCV co-infection, are now consistently between
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50% and 90% among IDUs in almost all countries in this region. End-stage liver
disease has become a major cause of mortality in Eurasia. Over two million people
inject drugs in Russia, which likely has more co-infected people than any other
country, particularly among the prison population. Harm reduction supported by
the Global Fund to Fight AIDS, Tuberculosis and Malaria has been successful in
the Ukraine, and countries with membership in the European Union have also
promoted the approach. Many people, however, lack access to harm reduction, in
particular, prisoners, street youth and sex workers.
1999, rates of 30% to over 70% among people who inject drugs have
recently been reported in Brazil, Argentina and Mexico. Co-infection with HIV
is over 90% in Puerto Rico, and over 80% in Argentina and Brazil. : While overall
HCV prevalence in these regions was estimated at less than 2% in Latin American
countries and very few Caribbean countries have harm reduction programs. Drug
use is criminalized in many countries and prisoners are often denied access to
condoms.
North Africa and the Middle East: While HCV prevalence was low in 1999, more
recent studies from North Africa and the Middle East now show HCV infection
rates  of  50% to  60%.  HCV prevalence  among people  who inject  drugs  in  Iran  is
reported as being as high as 80% and HIV/HCV co-infection as high as 87%. Drug
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use, as well as opposition to drug use, is on the rise and drug related offenses bring
severe penalties. While Iran and seven other countries have adopted and put into
place harm reduction pilot projects, the number of people reached remains
insufficient to stop the spread of co-infection.
Sub-Saharan Africa: In 1999, sub-Saharan Africa had the highest global
prevalence of HCV infection among the general population; over 5% of Africans
were estimated to be HCV-infected. There is limited data as to how HCV is spread
in Africa, but it is assumed that health service acquired (nosocomial) infection, and
transmission through non-sterile tattooing, circumcision and female genital
mutilation (FGM) equipment are underlying factors. There is also little data on
injection drug use in Africa, but if injection drug use does grow, it could fuel a
serious HIV/HCV epidemic in countries that already have high HIV prevalence.
South Africa, Mauritius, Kenya, Nigeria and Tanzania are reporting
increased numbers of IDUs. In one study, Kenya was reported to have HCV rates
of over 40% among people who inject drugs. Only Mauritius and South Africa
have harm reduction programs. There is no information available on HIV/HCV co-
infection, but some better-resourced HIV treatment programs have begun to screen
for HCV.
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MATERIALS AND METHODS
STUDY POPULATION:
A total of 100 newly diagnosed HIV patients were enrolled in the study from
whom attended the ART clinic in Madras Medical College and Government
General Hospital. Screening for HIV was done by ELISA, those who were found
positive were tested by repeat ELISA utilizing another blood sample & considered
HIV seropositive only if both samples were found to be positive
Patients selected for the study satisfied all the inclusion and exclusion
criteria; written consent was obtained from all patients participating in the study.
STUDY DURATION:
The  study  was  conducted  over  a  period  of  1  year  from  October  2009  to
October 2010.
STUDY DESIGN:
A single center cross-sectioned descriptive study design was chosen.
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METHODS:
Detailed clinical history was taken from each patient and complete review of
their case notes was performed. A complete examination was undertaken from
each patient.
INVESTIGATIONS:
         For ALL PATIENTS, the following investigations were done:
? Complete Blood Count
? CD4 count
? Screening of syphilis by VDRL
? HBsAg / Anti-HCV
? Anti-HSV-2-IgG in all patients
For SELECTED patients
? TPHA in patients who are VDRL reactive
? LFT and Ultrasonography of abdomen for those who are positive for
Hepatitis virus co-infection
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Inclusion criteria:
? Newly detected HIV patients
? Patients yet to be initiated on Highly Active Anti-Retroviral Therapy
? Those who are willing for the study
Exclusion criteria:
? Patients already on HAART therapy
? Known cases of liver disease
? Previously diagnosed syphilis / hepatitis / herpes on treatment
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OBSERVATION AND RESULTS
PROFILE OF 100 HIV PATIENTS IN THE STUDY
Male Female Transgender
62 36 2
Age<12 12-35 >35
4 46 50
Rural Urban
42 58
Illiterate School College
55 41 4
CD4<200 200-350 >350
36 30 34
Sexual route Blood transfusion IDU Vertical
71 11 13 5
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Figure 1. 50% of patients were asymptomatic and 50%  were symptomatic on presentation.
Symptomatic were in primary stage of infection. Asymptomatic ones probably in the early stages
of infection
Figure 2. VDRL titres were positive in 9 patients and TPHA positivity was seen only in 6
patients (67%); High VDRL titres has not been noted in HIV / Syphilis in our study.
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Figure 3. Sexual route is the commonest mode of transmission. In our study, we found 1 case of
syphilis in an IDU probably related to the use of blood-tainted shared syringes.
Figure 4. Most patients with syphilis (83%) have CD4 counts >200.
41
Figure 5. 15% of HIV patients were found to be infected with HSV-2.
Figure 6. Around three fourths of the patients were asymptomatic. The symptomatic patients
presented with painful genital ulcers.
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Figure 7. ONE out of FIFTEEN cases was transmitted through blood transmission and all others
were transmitted sexually.
Figure 8. HSV-2 infection was associated with low CD4 counts (<200).
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Figure 9. 40% cases were symptomatic and they presented to us with features of decompensated
liver disease and portal hypertension.
Figure 10. Three out of five cases acquired the disease sexually; 1 out of 5 was an IDU; the other
patient has acquired it probably through blood transfusion done per operatively during mitral
valve commisurotomy, three years back.
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Figure 11. Elevated ALP was seen in 80% of patients (4 in number; Out of them, two were
symptomatic).
Figure 12. CD4 count was low in 60% of patients.
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Figure 13. Elevation of liver enzymes was not related to CD4 counts.
Figure 14. Two symptomatic patients who had features of DCLD with portal hypertension had
findings in USG abdomen.
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Figure 15. All the patients were asymptomatic.
Figure 16. Four out of five patients were IDU. 1 patient has acquired via blood transfusion done
for appendicectomy 3 years back.
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Figure 17. CD4 count was <200 in 80% of patients.
Figure 18. Elevated ALT and ALP was seen in 60% of patients.
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Figure 19. CD4 count was virtually low in all patients with elevated ALT (100%) rather than
elevated ALP (60%).
Figure 20. USG abdomen was normal in all cases.
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Figure 21. HSV (15%)  was the commonest STI associated with HIV followed by syphilis (6%),
hepatitis B (5%) and hepatitis C (5%).
Figure 22. Most of the STIs were asymptomatic, highest noted in hepatitis C infection (100%),
followed by HSV-2 infections (33%), syphilis (50%) and hepatitis B (66%).
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Figure 23. Shows an overall predominance of HIV/STI coinfections, hepatitis C noted only in
males; Both the transgenders in our study showed evidence of HSV-2 infection.
Figure 24. Genito-ulcerative diseases showed no age preponderance, whereas hepatitis infections
were noted mostly in patients aged more than 35 years (80%).
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Figure 25. Genito-ulcerative diseases were more common in the rural people (66%) than the
urban people, however hepatitis C infection has been noted in more in the urban community
(80%).
Figure 26. Genito-ulcerative diseases were found in very high percentages (64%) in illiterate
people, whereas blood borne infections were common in the literate (66%).
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Figure 27. Sexual route of transmission has been the commonest mode of acquisition of
ulcerative lesions, though we detected two cases which were blood borne. Hepatitis B infection
was mostly sexually transmitted in our study, whereas hepatitis C was only blood borne.
Figure 28. Shows the routes of transmission of HIV in the study population. Sexual transmission
(71%) includes homosexual route of transmission (2%).
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Figure 29. Shows low CD4 counts (<200) associated with HSV-2 and hepatitis C infections.
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DISCUSSION
In our study, we intended to analyse 100 newly diagnosed HIV patients, who
attended our ART clinic in Madras Medical College and Government General
Hospital. All those who took part in our study fulfilled the inclusion criteria.
Patients on ART and other hepatotoxic drugs were excluded, as these may interfere
with  the  CD4  counts  and  liver  function  test  of  these  patients.  Patients  who  were
treated previously for the STIs may have altered clinical features and interference
with investigations, so were excluded from the study.
A complete demographic, clinical profile of these patients was taken.
Complete blood counts, liver function tests and investigations for Syphilis ( VDRL
screening and TPHA confirmation for VDRL reactive), Herpes Simplex 2 (anti
HSV-2 IgG ELISA), Hepatitis B,(HBsAg), Hepatitis C( anti-HCV) were done in
all patients. Ultrasonography was done for those who tested positive for co-
infected with hepatitis B or C infections, irrespective of their symptomacy.
Out of the 100 HIV positive patients studied, males accounted to 62% of the
cases, a preponderance as shown in many other previous studies. Most of those in
the study were urban residents (56%), probably due to study being conducted in a
tertiary care center. The literacy rate among the studied population was 45% (who
has their schooling was 41%, degree holders were 4%). Most of the IDU patients
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were literate. Sexual route of transmission was seen in 28% of among literates and
44% among illiterates.
The commonest route of transmission was found to be sexual (71%),
followed by IDU (13%), blood transfusion (11%), and vertical (5%). In contrast to
other studies wherein IDU made 2-5% of all cases, we had high percentage of IDU
(13%). This is probably due to an increased addressing of IDUs in Chennai and
also, Tamil Nadu being identified to harbor the maximum number of IDUs living
with HIV infection.85
A  symptom  analysis  was  done  in  all  the  100  patients  for  the  four  STIs
(syphilis, HSV-2, hepatitis B and hepatitis C) in detail. Symptoms of genital ulcers
were given by 10% and clinical examination revealed features of primary chancre
in 3% and herpes genitalis in 7%. However, all hundred patients were subjected to
VDRL and anti-HSV-2 IgG antibody detection. VDRL was reactive in 9 patients,
out of which three were symptomatic. We did not find high VDRL titres in our
study, in contrast to few other previous studies. These patients were subjected to
TPHA confirmation and we found it to be positive in six out of those nine. All of
these  confirmed  cases  ,  THREE  were  in  primary  stage  of  syphilis  and  all  three
symptomatics had multiple chancres; the other three asymptomatic TPHA positive
patients, were probably in early stages of syphilis. Hence, the distribution of
HIV/syphilis  coinfection  was  6%,  out  of  which  60%  were  males  with  no  age
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prelidiction, 66% being rural residents, CD4 counts were more than 350 in most
patients.
Patients with symptoms and signs suggestive of herpes genitalis proved to
have multiple tender genital ulcerations. In HIV/HSV-2 coinfections, tenderness
and necrosis of ulcers was found to be more severe than in HSV-2 infections alone.
All the patients in the study were analysed for anti-HSV-2 IgG antibodies.Among
the fifteen patients who tested. positive for anti-HSV-2 IgG,, of which seven were
symptomatic and eight were asymptomatic.  In the asymptomatic group with
HIV/HSV-2 coinfection, 50% of the patients gave past history of similar
complaints. Analysis of the fifteen who turned positive for anti-HSV-2 IgG
antibodies, revealed that nine out of fifteen were males; ten out of fifteen were
residents of rural areas/outskirts of the city, eleven out of fifteen were illiterates.
Two transgenders included in the study tested positive for HIV/HSV-2 coinfection
and were asymptomatic.
Symptoms of hepatitis were asked to all the 100 HIV patients. Among them
two patients presented with the history of gradually progressive abdominal
distension, one among the two gave history of hematemesis and malena of recent
onset. All the other 98 patients showed no symptoms of hepatitis either in the
present  or  in  the  past.  All  of  them  were  screened  for  HBsAg  and  anti-HCV
antibodies.
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HBsAg was found to be positive in 5% of individuals (five in number); two
of them presented to us with features of decompensated chronic liver disease and
portal hypertension. The other three of them were completely asymptomatic. Out
of the five patients with this coinfection, there were three males; three were urban
residents; four were literate. The mean CD4 counts in these coinfected patients was
found to be 297 cells/mm3. The route of transmission was sexual in three out of
five (60%). Liver enzymes were elevated in two patients who had features of
DCLD. Ultrasonography showed findings of cirrhotic liver and portal hypertension
only in the symptomatic group. Liver was normal in the asymptomatic
HIV/hepatits B coinfected patients.
Hepatitis C screening done in 100 patients showed prevalence of 5% in our
study,  out  of  which  IDU was  the  most  common route  of  transmission  (80%)  and
20% was transmitted through blood transfusion. All of them were males86,87; 80%
were literates; and 80% were urban residents. HIV/hepatitis C coinfection was
100% asymptomatic. Liver enzymes were elevated even in asymptomatics (60%).
CD4 counts were virtually low in all patients with elevated ALT. CD4 counts were
less than 200 in 80% of individuals with this coinfection. There was no patient co-
infected with both Hepatitis B and Hepatitis.C.
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Ultrasonography  of  abdomen  was  normal  in  all  the  patients  with
HIV/hepatitis C coinfection. The results of HIV/Hepatitis co-infection were in
concordance with the studies done by Padmapriyadarshini et al84
Overall,  analysis  of  all  the  100  HIV  patients  studied,  HSV-2  was  the
commonest STI associated. Most cases were asymptomatic, CD4 counts were low
in most patients with this co-infection; genital ulcers were more tender and
necrotic in many patients.
Syphilis  was  the  second  most  common  co-infection  with  HIV,  all  of  them
found to be in primary stage of infection. Like other studies, we also found
multiple chancres in few patients, but we never found very high VDRL titres in
patients with this co-infection.
Hepatitis B and C infections formed 5% each in being co-infected with HIV.
Hepatitis C remained completely asymptomatic in all the patients. Even then, liver
enzymes were elevated in majority of the patients with normal ultrasonographic
findings. CD4 counts were profoundly low (less than 200/mm3) in those with
elevated liver enzymes in HIV/hepatitis C co-infection rather than HIV/hepatits B
co-infection.
We had two patients presented as DCLD, found to have HIV/hepatitis B co-
infection. Mode of transmission was sexual in (60% of this co-infection). This was
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in contrast to HIV/hepatitis C co-infection where transmission was through IDU
and blood transfusion.
The mean age of HIV co-infected84 with Syphilis was 40 years, hepatitis B –
40 years,  hepatitis C – 37 years, HSV-2 – 30 years. CD4 counts remained
unaltered with HIV/syphilis or HIV/hepatitis B co-infection. While counts
remained low in case of HIV/hepatitis C and HIV/HSV-2 co-nfections. Most
patients with these co-infections were asymptomatic and hence mandatory
screening may be essential for these co-infections in all HIV patients.
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CONCLUSION
In this study, it is clearly shown that, out of 100 HIV patients
? Sexual route of transmission was found to be lesser (71% vs 87%) and IDU
was found to be higher (13% vs 2%) than that of national average.
? HIV/STI co-infection was common in males than females.
? Genito-ulcerative diseases were common in the illiterate and rural
population, whereas predominantly blood borne infections were common in
the literate and urban population.
? HIV/STI co-infections were overall higher in people >35 years of age.
? In all the four STIs studied, asymptomatic infections were higher (highest in
hepatitis C(100%), followed by Hepatitis B(60%), HSV-2(53%) and
syphilis(50%)
? HSV-2 infection remains the most common STI associated with HIV, many
of them being asymptomatic.
? Prevalence rate of HIV/HSV-2 co-infection is higher than that studied
elsewhere in Asia and in other states of India.
? Prevalence of HIV/syphilis co-infection is higher (6%) than the Indian
average of 4.34%, all of them were in early/primary stage of syphilis.
? Hepatitis C infection was asymptomatic in all those found to be positive.
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? Atypical presentation was noted in syphilis (as multiple primary chancres),
herpes simplex 2 (has more tender, necrotic ulcers)
? Five patients had HIV/Hepatitis B co-infection (two out of them presented as
DCLD with portal hypertension).
? Low CD4 counts were associated with hepatitis C and herpes simplex 2
infections whereas such a correlation was not seen with syphilis and
hepatitis B.
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PROFORMA
Name:                                                 Age:          Sex:        OP.NO:
Occupation: Income:
Education: Socioeconomic status:
Marital status:
Migration characteristics:
Address:                                              Ph.No:
PRESENTING COMPLAINTS:
Fatigability: Fever:
Jaundice: Abdominal distension:
Lymphadenopathy: Skin changes:
Pedal Edema: Loss of Wt:
Loss of Appetite: Bleeding Tendency:
Altered sensorium:
HISTORY:
H/O IV Drug use:
H/O Previous Blood transfusion:
Sexual history:
HIV status of father / mother / spouse / child:
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H/O solid organ transplant/ hemodialysis:
H/O sharing razors:
H/O occupational exposure:
H/O vaccination for hepatitis B
Co Morbid Illness:
EXAMINATION:
GENERAL EXAMINATION:
VITAL SIGNS:
EXAMINATION OF ORAL CAVITY:
EXAMINATION OF ABDOMEN:
EXAMINATION OF GENITALIA:
OTHER SYSTEMS EXAMINATION:
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INVESTIGATIONS
COMPLETE BLOOD COUNT:
LIVER FUNCTION TESTS:
CD-4 COUNT:
 HBS Ag :
ANTI-HCV ANTIBODY:
USG ABDOMEN(for those who have HIV/Hepatitis co-infection):
VDRL:
TPHA (For those who are VDRL reactive):
Anti HSV-2 IgG antibodies:
FINAL IMPRESSION:
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1 Stephen 37 M Urban S A A A IVD 6500 161 N R N N N - + R- - - AN
2 Suresh 38 M Urban I A A A IVD 5000 148 N N N N N - - R- - - AN
3 Raja 24 M Urban C A A A IVD 7300 102 N R R R N - + R- - - AN
4 Govindasamy 44 M Urban I A A A Blood 4900 552 N R N N N + - R- - - AN
5 Banu 33 F Urban S A A A Blood 7800 338 N N N N N - - R- - - AN
6 Vinitha 28 T Urban I A A S Sexual 5300 275 N  N  N  N  N  -  -  R-  -  +  AN
7 Swapna 28 T Urban I A A S Sexual 4900 168 N  N  N  N  N  -  -  R-  -  +  AN
8 Selvam 40 M  Rural  I A S A Sexual 5400 297 N  N  N  N  N  -  -  R+ + - AN
9 Ramanammal 30 F  Rural  I A A A Sexual 4700 471 N N N N N - - R- - - AN
10 Ramakrishnan 38 M Rural S A A A Sexual 5200 468 N N N N N - - R- - - AN
11 Jayanthi 41 F Urban S A A A Sexual 4800 575 N N N N N - - R- - - AN
12 Mohan Das 31 M Rural S A A A Sexual 5400 303 N N N N N - - R- - - AN
13 Anwar 42 M Urban S A A A Sexual 5400 479 N  N  N  N  N  -  -  R+ - - AN
14 Selvam 23 M Urban I A A A Sexual 5300 290 N N N N N - - R- - - AN
15 Ravi 43 M Urban I A A A Sexual 5200 340 N  N  N  N  N  -  -  R-  -  +  AN
16 Robert Singh 33 M Urban I A A A Sexual 4200 175 N N N N N - - R- - - AN
17 Balasubramani 34 M  Rural  I A A A Blood 6200 166 N N N N N - - R- - - AN
18 Arun Raj 24 M Urban S A A A Sexual 7200 338 N N N N N - - R- - - AN
19 Sooriya Kumar 37 M Urban S A S A Sexual 4200 238 N  N  N  N  N  -  -  R+ - - AN
20 Munusamy 39 M  Rural  I A A A Sexual 3400 543 N N N N N - - R- - - AN
21 Elangovan 37 M Urban I A A A IVD 3400 154 N  N  N  N  N  -  +  R-  -  -  AN
22 Ravishankar 33 M Urban I A A A IVD 5200 152 N N N N N - - R- - - AN
23 Manohar 4 M Urban NA A A A Blood 4600 563 N N N N N - - R- - - AN
24 Jegan 32 M Urban I A A A IVD 4200 166 N N N N N - - R- - - AN
25 Kamalakannan 45 M  Rural  I A S A Sexual 6200 261 N  N  N  N  N  -  -  R+ + - AN
26 Usha 26 F Urban S A A S Blood 5200 261 N N N N N - - R- - - AN
27 Dasarathan 38 M Rural S A A A Sexual 4600 490 N N N N N - - R- - - AN
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28 Nagammal 47 F Urban I A A A Sexual 5200 504 N N N N N - - R- - - R=
29 Mahesh 31 M Urban I A A A Sexual 1200 19 N  N  N  N  N  -  -  R-  -  +  AN
30 Kavatha 49 F  Rural  I A A A Blood 1200 43 N N N N R - - R- - - AN
31 Babu 30 M  Rural  I A A A IVD 6800 684 N N N N N - - R- - - AN
32 Vijayalakshmi 36 F  Rural  I A A A Blood 4200 120 N N N N N - - R- - - AN
33 Suresh 29 M Urban S A A A Sexual 8000 38 N N N N N - - R- - - AN
34 Anjalai 29 F Urban S A A A Blood 4200 240 N N N N N - - R- - - AN
35 Anbalagan 39 M Rural S A A A Sexual 6700 484 N N N N N - - R- - - AN
36 Krishnakumari 10 F Urban S A A A Vertical 4200 240 N N N N N - - R- - - AN
37 Rajendran 42 M Rural S A A A Blood 4200 340 N  N  N  N  N  -  +  R-  -  -  AN
38 Kadhar Moideen 40 M Urban I A A A IVD 6100 473 N N N N N - - R- - - AN
39 Manimegalai 34 F  Rural  I A A A Sexual 5200 472 N N N N N - - R- - - AN
40 Rajendran 35 M Urban S A A A IVD 2600 159 N  N  N  N  N  +  -  R-  -  -  AN
41 Nithya 10 F  Rural  I A A A Vertical 5200 1951 N N N N N - - R- - - AN
42 Naveen Kumar 5 M Urban NA A A A Vertical 6200 360 N N N N N - - R- - - AN
43 Meena 16 F Rural S A A A Vertical 4200 357 N N N N N - - R- - - AN
44 Rajeshwari 38 F Rural S A A A Blood 1200 82 N N N N N - - R- - - AN
45 Prakash 22 M Rural S A A A IVD 2100 150 N N N N N - - R- - - AN
46 Edward 40 M Urban S A A A IVD 7900 327 N R N N N - + R- - - AN
47 Ramadoss 45 M Rural S A A A Blood 6900 490 N  N  N  N  N  -  +  R-  -  -  AN
48 Selvi 35 F Rural S A A A Sexual 4200 80 N N N N N - - R- - - AN
49 Kuppusamy 38 M Urban S A A A Sexual 4200 519 N N N N N - - R- - - AN
50 Meena 16 F Rural S A A A Vertical 6400 240 N N N N N - - R- - - AN
51 Prakash 38 M Rural S A A A IVD 3300 543 N N N N N - - R- - - AN
52 Chinnasamy 50 M Urban I A A A Sexual 4300 239 N N N N N - - R- - - AN
53 Ponnurangan 45 M  Rural  I A A S Sexual 9400 310 N R N N N + - R- - - AN
54 Tamilarasi 30 F Urban S A A A Sexual 2400 381 N N N N N - - R- - - AN
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55 Ravikumar 29 M Urban S A A A Sexual 1200 508 N N N N N - - R- - - AN
56 Geetha 28 F Urban S A A A Sexual 2200 268 N N N N N - - R- - - AN
57 Vasantharani 29 F  Rural  I A A A Sexual 3300 154 N N N N N - - R- - - AN
58 Babu 32 M Urban I A A A Sexual 4400 299 N N N N N - - R- - - AN
59 Sowrirajan 58 M Urban I A A A Sexual 1200 93 N N N N N - - R- - - AN
60 Jayanthi 46 F Urban I A A A Sexual 3100 120 N  N  N  N  N  -  -  R-  -  +  AN
61 Krishnaveni 40 F Urban I A A A Sexual 1200 432 N N N N N - - R- - - AN
62 Musha 32 M  Rural  I A S A Sexual 3300 320 N  N  N  N  N  -  -  R+ + - AN
63 Sumathi 35 F  Rural  I A A A Sexual 1700 373 N N N N N - - R- - - AN
64 Vetrivendhan 32 M Urban S A A A Sexual 1200 354 N N N N N - - R- - - AN
65 Vijayasarathi 26 M Urban S S A A Sexual 4200 589 R  N  N  N  N  -  -  R-  -  +  AN
66 Veeralakshmi 29 F Rural S A A A Sexual 3100 316 N N N N N - - R- - - AN
67 Murugesan 52 M Urban I A A A Sexual 2100 631 N N N N N - - R- - - AN
68 Krishnan 32 M Urban I A S A Sexual 3100 267 N  N  N  N  N  -  -  R+ - - AN
69 Rajesh 34 M Urban I A A S Sexual 1500 93 N N N N N - - R- - - AN
70 Vijayalakshmi 23 F Urban I A A A Sexual 2300 654 N N N N N - - R- - - AN
71 Murugan 28 M Urban S A A A Sexual 1400 860 N N N N N - - R- - - AN
72 Dhanasekar 41 M  Rural  I A A A Sexual 1800 32 N  N  N  N  N  -  -  R+ + - AN
73 Rajesh 34 M Urban S A A A Sexual 3100 93 N N N N N - - R- - - AN
74 Malar 32 F  Rural  I A S A Sexual 1200 438 N  N  N  N  N  -  -  R+ - - AN
75 Prema 28 F  Rural  I A A A Sexual 1200 420 N N N N N - - R- - - AN
76 Shabana Begam 26 F Rural S A A A Sexual 3500 243 N  N  N  N  N  -  -  R-  -  +  AN
77 Younus Khan 30 M Urban S A A A Sexual 1400 283 N N N N N - - R- - - AN
78 Sekar 54 M Urban S A A A Sexual 4800 235 N N N N N - - R- - - AN
79 Aruna 35 F  Rural  I A A A Sexual 1200 52 N N N N N - - R- - - AN
80 Sandhyagu 32 M Urban C A A A Sexual 1400 110 N  N  N  N  N  -  -  R-  -  +  AN
81 Roslin Amutha 32 F Urban S A A A Sexual 1400 122 N N N N N - - R- - - AN
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82 Senthil 22 M  Rural  I A A A Sexual 1400 282 N  N  N  N  N  -  -  R-  -  +  AN
83 Malarkodi 32 F Urban I A A A Sexual 1400 154 N N N N N - - R- - - AN
84 Edward 43 M Urban S A A A Sexual 4800 336 N N N N N - - R- - - AN
85 Sathyamoorthy 42 M Urban S A S A Sexual 1400 409 N  N  N  N  N  -  -  R+ - - AN
86 Amsa 40 F  Rural  I S A A Sexual 6300 194 R R R R R + - R- - + N
87 Kanniyammal 47 F  Rural  I S A A Sexual 10600 369 R R R R R + - R+ +  -  N
88 Leela 40 F Urban I A A A Sexual 600 307 N N N N N - - R- - - AN
89 Balu 38 M  Rural  I A A A Sexual 4200 449 N  N  N  N  N  -  -  R-  -  +  AN
90 Santhosam 33 M Urban I A S A Sexual 1400 120 N  N  N  N  N  -  -  R+ + - AN
91 Uma 34 F  Rural  I A A A Sexual 5600 238 N N N N N - - R- - - AN
92 Mallika 35 F  Rural  I A A S Sexual 1400 320 N  N  N  N  N  -  -  R-  -  +  AN
93 Arumugam 37 M  Rural  I A A S Sexual 1400 110 N  N  N  N  N  -  -  R-  -  +  AN
94 Perumal 50 M Rural S A A A Sexual 1400 304 N  N  N  N  N  -  -  R-  -  +  AN
95 Parvathi 48 F  Rural  I A A A Sexual 1200 309 N N N N N - - R- - - AN
96 Raghu 40 M Urban I A A A Sexual 1200 208 N N N N N - - R- - - AN
97 Rekha 34 F Urban S A A A Sexual 25000 187 N N N N N - - R- - - AN
98 Selvam 45 M  Rural  I A A A Sexual 11100 12 N N N N N - - R- - - AN
99 Anbalagan 40 M  Rural  I A A A Sexual 2700 96 N N N N N - - R- - - AN
100 Mariyammal 40 F  Rural  I A A A Sexual 7200 368 N N N N N - - R- - - AN
I-Illiterate      S-school      c-college      N-Normal       R+ REACTIVE      R-  NON-REACTIVE     AN-nil abnormality       N-
ABNORMAL
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